It’s with an enormous sense of pride, satisfaction, and relief that I can share that
@MAPS
learned that the first of two Phase 3 studies of MDMA-assisted psychotherapy for PTSD was statistically significant and is considered a successful Phase 3 study:
On the front page of today's
@NYTimes
,
@AndrewJacobsNYT
profiles MAPS Founder
@RickDoblin
, Ph.D., and highlights the success of MAPS' first Phase 3 study of MDMA-assisted therapy for PTSD, the results of which were published in
@NatureMedicine
today.
I am thrilled to announce that the recording of my Ted Talk about psychedelic research is now available! On the main stage at TED2019, I spoke on how psychedelics can shift the field of mental health and MAPS’ MDMA-assisted psychotherapy research.
My 4th appearance on the
@JoeRogan
Experience was just released—check it out!
#JRE
Thanks to Joe for hosting me and bringing visibility to
@MAPS
at such a critical moment in the
#psychedelic
movement.
Today, The
@Guardian
published my op-ed outlining why
@MAPS
envisions a day when psychedelics will be more than a last-ditch treatment: they will be a catalyst for mass mental health.
100,000 is a very large number of therapists, but considering the millions of people with PTSD and depression, it’s not unreasonable.
@MAPS
aims to train 25,000 therapists in MDMA-assisted therapy for PTSD by 2030.
@LAWeekly
@Berkeley_Psyche
@MichaelPollan
We are delighted to see legal access to psychedelics for spiritual, health, or personal growth join cannabis reform as a popular and bipartisan issue despite the barriers imposed by antiquated drug policies.
MAPS releases a public statement following the passage of all nine statewide ballot measures to reform
#drug
policies across the
#UnitedStates
, including the first measure to
#decriminalize
drug possession in Oregon with a Portugal-inspired approach.
If we do succeed with our second Phase 3 study of MDMA-assisted therapy for PTSD, the whole field of psychedelic psychotherapy will have been proven in one instance, serving as the pathbreaker with the FDA.
@MAPS
@TODAYShow
@NBC
@SavannahGuthrie
@JonLubecky
MAPS is on The
@TODAYShow
!
We are excited to see the results of MAPS-sponsored research reaching mainstream audiences as we continue to advocate for increased access to
#psychedelic
therapy.
Watch
@NBC
's interview with MAPS Founder
@RickDoblin
, Ph.D.:
Paired with his audacious dedication to humanizing people who use drugs,
@DrCarlHart
challenges the fear-based dogmas of the War on Drugs. Welcome to the
@MAPS
Board of Directors, Carl!
MAPS is honored to announce the election of
@DrCarlHart
to our Board of Directors!
Dr. Hart's decades of experience have compelled him to examine how the
#WarOnDrugs
has shaped and reinforced global structural inequities.
Join us in welcoming Dr. Hart!
Today is my 64th birthday! What a great time to be alive—we’re witnessing the revival of psychedelic research, the turning of the tide for marijuana prohibition, and MDMA is on the way to becoming a legal prescription medicine.
Wow! What a special moment it was when I discovered that I reached 50K followers on Twitter! Thank you for being here, expressing interest in my life's work, and supporting our team at
@MAPS
at this critical moment in our 36-year history.
Pioneering psychedelic researcher and spiritual teacher Baba Ram Dass, born Richard Alpert, passed away on Sunday, December 22, 2019. Ram Dass was a great inspiration to thousands/millions of people including me.
We commend FDA for recognizing the great unmet medical need of PTSD by allowing access to MDMA-assisted psychotherapy on a compassionate basis for people with treatment-resistant PTSD. We are delighted to begin generating real-world evidence about this potential new treatment.
Today, MAPS is announcing that the U.S. Food and Drug Administration (FDA) has agreed to MAPS’ application for an
#ExpandedAccess
program for
#MDMA
-assisted
#psychotherapy
for
#PTSD
, which will allow 50 patients to receive MDMA-assisted
#psychotherapy
.
Prior Positive Results Confirmed in
@MAPS
-Sponsored, Philanthropy-Funded Phase 3 Trial
Today, we can imagine that MDMA-assisted therapy for PTSD may soon be available and accessible to all who could benefit.
At 36,
@MAPS
is now older than I was when I started MAPS at age 32. Personally, it's been a blessing to see so much progress and healing in my own lifetime.
From all of us at MAPS, thank you so much for helping us move closer to making legal psychedelic medicine possible!
Happy 36th anniversary to us!
On April 8, 1986, MAPS was founded by
@RickDoblin
, Ph.D. Today, we are closer than ever to legalizing
#MDMA
-assisted therapy for PTSD, though there is still a long road ahead.
Celebrate our anniversary with a gift to MAPS:
After 32 years of hard work,
@MAPS
is about to begin Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD. Donate today and your donation will be doubled:
As I celebrate my 66th birthday today, I reflect on the gift of generous support throughout the years from family, friends, colleagues, and the psychedelic community. Thank you!
Happy 66th birthday to MAPS Founder and Executive Director
@RickDoblin
, Ph.D.! Today, we celebrate Rick’s leadership, achievements, and over 33 years of dedication to expanding
#psychedelic
science and medicine.
Give Rick a
#birthday
gift:
#HappyBirthday
We think it’s going to require a decade of psychedelic clinics being rolled out for people to hear about the positive experiences. We’ll have licensed legalization, I think, in 2035.
#Harvard
Law Today covers the launch of the Project on
#Psychedelics
Law and Regulation (POPLAR) at
@Harvard_Law
School's
@PetrieFlom
Center for Health Law Policy, Biotechnology, and Bioethics.
Check out the event highlights and recordings!
As a result of this study and through the persistent and consistent application of scientific rigor, we have demonstrated that MDMA-assisted therapy is likely to provide relief for people diagnosed with PTSD.
The first Phase 3 trial of
#MDMA
-assisted therapy for posttraumatic stress disorder (
#PTSD
) replicated and expanded on Phase 2 results indicating MDMA-assisted
#therapy
may be an effective and cost-saving treatment for PTSD resulting from any cause. (1/6)
It was great to sit down with
@JoeRogan
for my third appearance on the
#JoeRoganExperience
. Amazingly, we did the interview without smoking marijuana!
In the podcast, we discuss the successes and challenges of
@MAPS
' work in the psychedelic field.
The successful completion of two Phase 3 studies for PTSD gives us hope for MDMA-assisted therapy & all
#psychedelics
.
The
#psychedelic
movement is expanding & building community at
@PsychedelicSci
!
Join us from June 19-23 in Denver
In one small example of retaining the soul of
@MAPS
, I’m happy to report that our employment manual includes a concept called "smokable tasks." These are work tasks that a staff member does better while under the influence of marijuana!
"We’re passionately committed to retaining our soul as we develop a larger corporate structure."
—
@RickDoblin
, Ph.D., MAPS Founder and Executive Director
Read Doblin's full update in the latest edition of the
#MAPSBulletin
:
@elonmusk
@insidepharma
@jimcramer
At the non-profit
@MAPS
, we have a plan to bring MDMA-assisted therapy to millions in need. We can achieve it with $150M over three years ($50M/year) in donations from our generous supporters.
Let me know if you’d like to connect,
@ElonMusk
.
In MDMA-assisted therapy, the treatment is not the drug—the drug is just a tool. It's the relationship that we have with it that makes the difference.
Listen to the full episode of the Bialik Breakdown with
@MissMayim
Bialik:
The results of the interim analysis of MAPS’ pivotal first Phase 3 trial are the most powerful evidence yet that MDMA-assisted psychotherapy could help transform the lives of people suffering from PTSD.
Now streaming:
@Netflix
's "How to Change Your Mind” series!
Based on the book by
@MichaelPollan
, Chapter 3:
#MDMA
spotlights MAPS’
#psychedelic
research with MDMA-assisted therapy. Help change minds by spreading awareness!
Now streaming:
@Netflix
's "How to Change Your Mind” series!
Based on the book by
@MichaelPollan
, Chapter 3:
#MDMA
spotlights MAPS’
#psychedelic
research with MDMA-assisted therapy. Help change minds by spreading awareness!
MDMA was a therapy drug before it became a party drug. Last night, I joined
@FoxBusiness
' Kennedy to discuss
@MAPS
' efforts to bring MDMA back to therapy.
Thanks for your support of MAPS,
@KennedyNation
! We hope to see you at
@PsychedelicSci
2023.
The Pineapple Fund's outstanding generosity exemplifies how the growth of cryptocurrency can be leveraged for profound social change. The blockchain community is helping to lead the way in giving the gift of MDMA-assisted psychotherapy to the world in order to heal trauma.
Yesterday, the Pineapple Fund donated 59.89
#Bitcoin
(BTC), with a value of $1,000,000, to the Multidisciplinary Association for
#Psychedelic
Studies (
@MAPS
). We are thankful and inspired by the
#PineappleFund
's plan to
#donate
over $86 million in
#BTC
.
Wellness check results are in: alive and well! Working hard with the
@MAPS
team to make MDMA a medicine. I hope that our work toward reducing the stigma surrounding psychedelics inspires you to help reduce the stigma about offices like mine,
@RateMySkypeRoom
!
In
@CrookedMedia
's Lovett or Leave It podcast,
@JonLovett
and I have a lively discussion about the history of MDMA,
@MAPS
' recent MDMA/PTSD research, and how society can achieve mass mental health through a system of licensed legalization for all drugs.
Many thanks to
@LexFridman
for hosting me on his podcast!
Listen as we have an excellent conversation about the history of psychedelics in culture and research, the ways in which
@MAPS
is working to shape the future of psychedelics, and much more.
These long-term follow-up findings show that once people with PTSD learn that they can productively process traumatic memories instead of suppressing them, they can continue to heal themselves even after they have stopped receiving MDMA-assisted psychotherapy.
Explore the resurgence of psychedelic research, including
@MAPS
-sponsored clinical trials of MDMA-assisted therapy for PTSD, in a new
@PBS
program! Now streaming on
@NOVAPBS
, YouTube, and the PBS Video app.
The blockchain community is helping to lead the way, not only in decentralized technologies and currencies, but in giving the gift of MDMA-assisted psychotherapy to the world in order to heal trauma and bring greater compassion to psychiatry and medicine.
At last year's World Economic Forum (
@WEF
) in Davos, I forecast the future of psychedelic legalization. Through our work at
@MAPS
, I predict that there will be thousands of psychedelic clinics and enhanced access to psychedelics in the next decade.
We can now truly say that
#MDMA
-assisted psychotherapy will be a gift to the world from the
#psychedelic
and
#cryptocurrency
communities, with
@MAPS
having been unable to obtain any government funding for our research.
Today,
@MAPS
is proud to announce the successful completion of the $4 million matching grant from the
#PineappleFund
for
@US_FDA
Phase 3 clinical trials of
#MDMA
-assisted psychotherapy for
#PTSD
. Thank you to everyone who donated!
In challenging times, we are reminded of the importance of gathering in community. Next week, I'll be in Black Rock City for
@BurningMan
, and I hope to see you there!
Image by
@Nirvan
for
@WhatATripFilm
It is a fundamental violation of
#HumanRights
to block access to drugs that change people's
#consciousness
. We should be regulating people's behaviors, not their thoughts. Or their feelings.
The overall goal is to have a more spiritualized humanity that can, instead of fighting each other, address our common challenges, such as climate change and the rise of authoritarianism.
via
@BulletinAtomic
/
@RobertKElder
Rick Doblin and Carol Rosin gave MDMA to Soviet scientists and military personnel set to negotiate with US President Ronald Reagan in 1985.
Even now, they still believe introducing psychedelics in nuclear talks can produce positive results.
@C_Angermayer
@tferriss
@michaelpollan
@RCarhartHarris
As
@C_Angermayer
notes, easier access to capital is a key advantage of for-profit psychedelic drug development over non-profit drug development reliant on philanthropy.
However, Christian is not correct that patents are essential to obtain exclusive rights to market a medicine.
I look forward to speaking in the sixth and final session of
@PennNursing
's psychedelic education series on March 30. Attend one or more sessions in this free series to expand your psychedelic knowledge! The series begins on January 19.
Kick off the new year by joining us for a free, virtual learning series on psychedelics. The first event takes place on January 19 with an introduction to psychedelics, including historical roots and their emergence into Western medicine. Learn more: .
"So where did this research suddenly come from?" asks Paul Frysh of
@WebMD
.
There's nothing sudden about it! The promise was all there in the psychedelic research from the '50s and '60s—all you had to do was look.
Explore
@WebMD
's psychedelic series:
Top healthcare site
@WebMD
publishes a multi-part series about
#psychedelic
-assisted
#therapy
! Explore this series for an overview of current
#research
, perspectives from experts in the field including
@RickDoblin
, Ph.D., and psychedelic FAQs.
(1/3)
My new article for
@TIME
covers how U.S. and global drug prohibition has, for decades, delayed medical research into the healing properties of Schedule 1 drugs.
Today is the 34th anniversary of the history of MAPS! I can only be delighted to think about what's going to happen in the next 34 years. Join me at 4:20 ET for a live stream Q&A on the MAPS Facebook page!
Today is MAPS' 34th anniversary! April 8, 1986, MAPS was founded as a non-profit
#psychedelic
research and
#educational
organization by
@RickDoblin
, Ph.D. Join the
#LiveStream
Q&A session today at 4:20 PM Eastern with Rick Doblin on our Facebook page.
I started MAPS in 1986 as a non-profit psychedelic pharmaceutical company with the goal of making MDMA a prescription medicine. If we can get a fair amount of donations, we may be able to make MDMA-assisted psychotherapy for PTSD a legal treatment by 2021.
I recently had prostate cancer surgery. Early detection & advanced technology led to my positive outcomes with no evidence of spread, allowing me to continue mainstreaming psychedelics with
@MAPS
!
I encourage everyone to pursue regular cancer screening.
In a step towards the destigmatization of psychedelics, U.S. Army SGT(R)
@JonLubecky
of
@MAPS
and I attended
@RepDanCrenshaw
's Healthcare Innovation Summit to discuss the groundbreaking, nonpartisan psychedelic research conducted by MAPS.
Watch:
I'd like to wish a Happy Birthday to Stanislav Grof, one of my mentors who has taught me valuable lessons about psychedelics, therapy, and nonordinary states of consciousness.
His research has laid the foundation for much of my work
@MAPS
and the field writ large.
In an interview with
@SkipperClay
of
@GQMagazine
, MAPS Founder and Executive Director
@RickDoblin
, Ph.D., discusses the origins of MAPS, his personal experience with
#psychedelics
, and a future society in which psychedelics are responsibly integrated.
The completion of data gathering in our second Phase 3 study of MDMA-assisted therapy for PTSD is a critical milestone in
@MAPS
’ 36-year campaign to obtain FDA approval for the therapeutic use of MDMA. (1/2)
MAPS is proud to share MAPS Public Benefit Corporation's announcement that the final participant in the second Phase 3 trial of
#MDMA
-assisted therapy completed their final session in the clinical trial treatment protocol.
MAPS is excited to take center stage in an episode of the highly anticipated
@Netflix
series
#HowToChangeYourMind
based on the best-selling book by
@MichaelPollan
! Watch the trailer and mark your calendar for the series debut on Tuesday, July 12.
Completion of the Phase 3 trials, made possible by generous donors to the $30 million Capstone Campaign, is a crucial moment in the potential approval of what may soon be the first broadly legal psychedelic-assisted therapy.
MAPS and the
#Psychedelic
Science Funders Collaborative (PSFC) today announced the completion of the Capstone Campaign, a non-profit fundraising effort to fund the final research required to seek U.S. FDA approval of
#MDMA
-assisted psychotherapy for
#PTSD
.
It is my sincere delight to introduce to our MAPS community, Ana LaDou, MAPS’ new Chief Operating Officer (COO). We are thrilled to have Ana join the team at MAPS, bringing with her almost two decades of experience in nonprofit leadership.
In my early twenties, I was trying to get to the core self without all of the compromises of civilization when I started raising a wolf cub named Phaedrus. It was great to speak with Sarah Rose Siskind (
@SRSiskind
) about this experience!
Thanks to Walter Reed National Military Medical Center (
@WRBethesda
) for hosting me at yesterday's Grand Rounds. I was pleased to present about
@MAPS
-sponsored research of MDMA-assisted therapy for PTSD to an audience of military psychiatrists and psychotherapists.
On my birthday today, I am feeling so grateful for everyone who has supported
@MAPS
and me over the years.
To celebrate my 69th birthday, consider donating $69+ to MAPS. Using this link, you might even win a prize—more details on
@MAPS
' profile later!
Follow along with
@MAPS
as we prepare to celebrate our 35th anniversary in 35 days! Between now and April 8, the day I founded MAPS in 1986, MAPS is sharing highlights from each year of its psychedelic history.
#MAPS35
: As we approach our 35th
#anniversary
on April 8, we are sharing highlights from each year of MAPS’
#history
! In 1986,
@RickDoblin
founded MAPS as an official 501(c)(3)
#NonProfit
. Later that year, Doblin sued the DEA for the first time.
It’s profoundly satisfying to see this occurring, about half a century after the backlash to the psychedelic 1960s and the criminalization, stigmatization, exaggerated risk estimates, and suppression of research into benefits that followed.
When I started
@MAPS
in 1986, there was no government funding for this research. Psychedelic research was still completely shut down.
See how far we've come in this new video from
@BBC_Reel
!
In a new 10-minute
@BBC_Reel
documentary,
@BBC
explores the potential of psychedelic-assisted therapy and MAPS Founder
@RickDoblin
, Ph.D., shares perspective about MAPS-sponsored research of
#MDMA
-assisted therapy for the treatment of PTSD.
A Message from our founder,
@RickDoblin
: FDA Decision, Redoubling of MAPS Efforts, Lykos Board Resignation.
These have been very challenging times at MAPS, at Lykos, in the entire psychedelic ecosystem, and in the world at large. This moment is sobering, yet it anchors me and
The Future of Psychedelics: Drug Development & Policy Reform
My psychedelic talk has the chance to hit the stage at
@SXSW
2024, and community support can make it happen. Cast your vote on
#SXSW
PanelPicker before August 20!
We are bringing people together from all over the world who are interested in
#psychedelics
for
@PsychedelicSci
!
Join
@MAPS
and the psychedelic community at
#PS2023
from June 19-23, in Denver, CO:
I am grateful for the long-term strategic and philanthropic support that MAPS has received from David Bronner and the Bronner family. The support MAPS has received is pivotal to our ability to gather data on MDMA-assisted psychotherapy for PTSD.
MAPS Founder
@RickDoblin
, Ph.D., reflects on MAPS' 34 years of
#psychedelic
research and
@DrBronner
's contributions to MAPS' mission through the Heal Soul campaign and beyond.
.
@MAPS
' research of MDMA-assisted therapy for PTSD will be featured in a psychedelic-focused
@NOVAPBS
program! Catch the premiere this Wednesday, October 19, at 9:00 PM (ET).
We're inspired and deeply grateful to the Mercer Family Foundation for their commitment to America's veterans and to the field of psychedelic science. They are to be commended for their gift.
Listen to my recent appearance on the
@AubreyMarcus
Podcast to understand
@MAPS
' multiple research, policy, and education priorities in the context of our larger, long-term goal of mass mental health!
"Since 1966, the National Institutes of Health has only funded
#psychedelic
research in very limited capacities, making organizations like MAPS, which solicits donations for research, even more important."
via
@TheCrimson
Thank you to everyone in the MAPS community who helped us raise $386,140 for our year-end fundraising campaign! With the continued support of MAPS donors, I am confident that this year will be even more astonishing than last year.
Thank you to our
#community
for the inspiring abundance of gifts to our year-end fundraising
#campaign
! A total of 1,875
#donors
from 43 countries contributed $386,140, reaching 129% of our initial $300,000 year-end fundraising goal.
FDA approval of whole plant medical marijuana would mean that patients could have their medical marijuana covered by insurance, although that possibility is currently blocked by the Department of Justice-enforced NIDA monopoly on marijuana for research.
Listen to the
@Drug_Science
Podcast, where I speak with
@ProfDavidNutt
about
@MAPS
' 35-year history, current project updates, and future vision for the next 35 years of psychedelic progress.
At this moment, when MDMA-assisted therapy for PTSD is closer to potential FDA approval than ever before,
@MAPS
and MAPS PBC must faithfully retain our values against the sometimes diametric values of the systems in which we operate.
@Psyched_Alpha